Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes

Molecular Medicine

Volumn 17, Issue 11, 2011, Pages 1223-1232

  Newrzela, Sebastian ^a   Cornils, Kerstin ^b   Heinrich, Tim ^a   Schläger, Julia ^a   Yi, Ji Hee ^a   Lysenko, Olga ^a   Kimpe, Janine ^c   Fehse, Boris ^b   von Laer, Dorothee ^c  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; RAG1 PROTEIN; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARCINOGENESIS; CD4 CD8 RATIO; CELL CLONE; CELL GROWTH; CELL IMMORTALIZATION; CELL MATURATION; CELL POPULATION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INTERACTION; GENE TRANSFER; IL15RA GENE; IL2RA GENE; IN VITRO STUDY; LMO2 GENE; MALIGNANT TRANSFORMATION; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTO ONCOGENE; RETROVIRUS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TRANSACTIVATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELL LINE, TRANSFORMED; CELL PROLIFERATION; CLONE CELLS; GENETIC VECTORS; HUMANS; INTERLEUKIN-2; LIM DOMAIN PROTEINS; MICE; MICE, INBRED C57BL; MUTAGENESIS, INSERTIONAL; PHENOTYPE; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, INTERLEUKIN-15; RECEPTORS, INTERLEUKIN-2; RETROVIRIDAE; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; VIRUS INTEGRATION;

EID: 82855172228     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2010.00193     Document Type: Article

References (39)

1. Li Z, et al. (2002) Murine leukemia induced by retroviral gene marking. Science. 296:497.
2. Modlich U, et al. (2005) Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood. 105:4235-46.
3. Stein S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 16:198-204.
4. Hacein-Bey-Abina S, et al. (2008) Insertional oncogenesis in 4 patients after retrovirusmediated gene therapy of SCID-X1. J. Clin. Invest. 118:3132-42.
5. Hacein-Bey-Abina S, et al. (2003) A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348:255-6.
6. Hacein-Bey-Abina S, et al. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 302:415-9.
7. Howe SJ, et al. (2008) Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118:3143-50.
8. Laufs S, et al. (2004) Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns. Mol. Ther. 10:874-81.
9. Wu X, Li Y, Crise B, Burgess SM. (2003) Transcription start regions in the human genome are favored targets for MLV integration. Science. 300:1749-51.
10. Baum C, von Kalle C. (2003) Gene therapy targeting hematopoietic cells: better not leave it to chance. Acta Haematol. 110:107-9.
11. Kustikova OS, et al. (2009) Cell-intrinsic and vector- related properties cooperate to determine the incidence and consequences of insertional mutagenesis. Mol. Ther. 17:1537-47.
12. Deeks SG, et al. (2002) A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol. Ther. 5:788-97.
13. Mitsuyasu RT, et al. (2000) Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood. 96:785-93.
14. Recchia A, et al. (2006) Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc. Natl. Acad. Sci. U. S. A. 103:1457-62.
15. Walker RE, et al. (2000) Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood. 96:467-74.
16. Newrzela S, et al. (2008) Resistance of mature T cells to oncogene transformation. Blood. 112:2278-86.
17. Nagai T, et al. (2002) A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. Nat. Biotechnol. 20:87-90.
18. Rizzo MA, Springer GH, Granada B, Piston DW. (2004) An improved cyan fluorescent protein variant useful for FRET. Nat. Biotechnol. 22:445-9.
19. Kalamasz D, et al. (2004) Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and Anti-CD28 antibodies. J. Immunother. 27:405-18.
20. Schmidt M, et al. (2001) Detection and direct genomic sequencing of multiple rare unknown flanking DNA in highly complex samples. Hum. Gene Ther. 12:743-9.
21. Currier JR, Robinson MA. (2001) Spectratype/ immunoscope analysis of the expressed TCR repertoire. Curr. Protoc. Immunol. Chapter 10: Unit 10.28.
22. Hintzen RQ, et al. (1993) Regulation of CD27 expression on subsets of mature T-lymphocytes. J. Immunol. 151:2426-35.
23. Schmitt TM, et al. (2004) Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro. Nat. Immunol. 5:410-7.
24. Ambrogio C, et al. (2009) NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. Cancer Res. 69:8611-9.
25. Mathas S, et al. (2006) Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat. Immunol. 7:207-15.
26. Takahashi K, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 131:861-72.
27. Takahashi K, Yamanaka S. (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 126:663-76.
28. Woods NB, Bottero V, Schmidt M, von Kalle C, Verma IM. (2006) Gene therapy: therapeutic gene causing lymphoma. Nature. 440:1123.
29. von Laer D. (2009) Peaceful coexistence or clonal dominance? Blood. 114:3507-8.
30. Gilliland DG, Tallman MS. (2002) Focus on acute leukemias. Cancer Cell. 1:417-20.
31. Hahn WC, Weinberg RA. (2002) Rules for making human tumor cells. N. Engl. J. Med. 347:1593-603.
32. Kohn DB, Sadelain M, Glorioso JC. (2003) Occurrence of leukaemia following gene therapy of X-linked SCID. Nat. Rev. Cancer. 3:477-88.
33. Lamprecht B, et al. Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat. Med. 16:571-9, 1p following 579.
34. Smith KA. (1988) Interleukin-2: inception, impact, and implications. Science. 240:1169-76.
35. Willerford DM, et al. (1995) Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity. 3:521-30.
36. Lodolce JP, et al. (1998) IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity. 9:669-676.
37. Fehniger TA, et al. (2001) Fatal leukemia in interleukin-15 transgenic mice. Blood Cells Mol. Dis. 27:223-30.
38. Hsu C, et al. (2007) Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. Blood. 109:5168-77.
39. Charo J, et al. (2005) Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Res. 65:2001-8.